Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
Michael J. Keating(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Maher Albitar(Quest Diagnostics (United States)), Alice Lynn(The University of Texas MD Anderson Cancer Center), Susan Lerner(The University of Texas MD Anderson Cancer Center), William Plunkett(The University of Texas MD Anderson Cancer Center), Deborah A. Thomas(The University of Texas MD Anderson Cancer Center), Francis J. Giles(Northwestern University), Michelle A. Detry(Berry & Associates (United States)), Michael Andreeff(The University of Texas MD Anderson Cancer Center), Susan O’Brien(The University of Texas MD Anderson Cancer Center), Charles Koller(The University of Texas MD Anderson Cancer Center), Jörge E. Cortes(The University of Texas MD Anderson Cancer Center), William G. Wierda(The University of Texas MD Anderson Cancer Center), Stefan Faderl(The University of Texas MD Anderson Cancer Center)
Cited by 951
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k